This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Trius Therapeutics (antibacterials) raised $30mm in its Series B financing round led by first-time investor Kleiner, Perkins, Caufield & Byers, which contributes a member to the company's board. Other new backer FinTech Global Capital was joined by Series A shareholders Sofinnova Ventures, Versant Ventures, Interwest Partners, and Prism VentureWorks. Trius will use the money to move its oxazolidinone antibacterial compound TR701 through Phase II clinical trials.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?